Fortis Healthcare Q4 FY26: PAT jumps 44%, FY26 revenue up 17%

Key takeaway from the March quarter

Fortis Healthcare reported a sharp year-on-year rise in profitability for Q4 FY26, supported by higher operating revenue and a steep reduction in exceptional losses. Consolidated profit after tax (PAT) rose 44.2% to ₹271 crore versus ₹188 crore in Q4 FY25. Consolidated revenue from operations increased 17.8% to ₹2,365 crore from ₹2,007 crore a year ago. The company also pointed to steady execution in its core hospital business, which it said now contributes 85% of overall revenues. Alongside earnings, Fortis reiterated its focus on both brownfield expansion and inorganic growth in its priority clusters.

Headline numbers: Q4 FY26 and FY26

For Q4 FY26, Fortis reported an operating EBITDA increase of 22.2% year-on-year, with margin at 22.5% versus 21.7% in Q4 FY25. For the full year FY26, consolidated revenues stood at ₹9,128 crore, up 17.3% over FY25. Operating EBITDA for FY26 increased 31.3%, with margin at 22.8% versus 20.4% in FY25. Full-year PAT rose 31.5% to ₹1,064 crore. The numbers point to a year in which profitability grew faster than revenue, while margins also improved.

Exceptional losses fell sharply in Q4 FY26

Fortis attributed a major part of the Q4 profit growth to lower exceptional losses. Exceptional losses in the March quarter fell by nearly 76% year-on-year to ₹1,249 crore, down from ₹5,357 crore in Q4 FY25. The company’s Q4 FY26 PAT still rose despite these losses, suggesting stronger underlying operating performance combined with a smaller exceptional hit than the year-ago quarter. The change in exceptional items is a key reason the headline PAT growth outpaced revenue growth.

Hospital business drove growth, supported by volumes

Fortis said revenue growth was supported by strong performance across both its hospital and diagnostics businesses. The hospital business posted a 19% year-on-year revenue increase in Q4 FY26, aided by improved occupancy and higher average revenue per occupied bed (ARPOB). ARPOB rose 2% year-on-year to ₹2.56 crore. Occupancy in Q4 FY26 was 68%, compared with 69% in Q4 FY25. The company also reported that occupied beds increased to 3,339 compared with 2,855 in Q4 FY25, a growth of 17.0%.

Diagnostics business: double-digit growth in Q4 FY26

The diagnostics business reported 11% year-on-year revenue growth to ₹387 crore in Q4 FY26. Fortis linked this improvement to higher revenue contribution from its preventive portfolio. With hospitals accounting for the bulk of consolidated revenues, diagnostics remains a smaller but meaningful contributor within the group’s broader healthcare delivery model. The quarter’s diagnostic growth complemented the hospital upcycle in volumes and case mix.

Specialty mix: renal sciences and orthopaedics stood out

Management highlighted continued momentum in key clinical programs and specialty lines. Fortis said that for FY26, its top six specialties grew 19%. Among these, Renal Sciences and Orthopedics recorded growth of 22% and 21%, respectively. The company also said it has maintained investment momentum in medical equipment and technology to deepen clinical capabilities. In a hospital-led business, specialty performance and clinical depth often influence ARPOB and margins.

Network expansion: acquisitions and leases added ~500 beds

Fortis said it expanded its network in key geographies through brownfield initiatives and acquisitions. As part of its inorganic growth strategy, it added approximately 500 beds through the acquisition of People Tree Hospital in Bengaluru, the Shrimann Hospital in Jalandhar, Punjab, and a long-term lease arrangement for a Greater Noida hospital in Delhi-NCR. As of March 31, 2026, Fortis operated 6,152 beds across its network. Management also said it continues to actively evaluate further inorganic growth opportunities within its focus geographic clusters.

Forward capacity pipeline: 1,800 beds planned through FY30

Alongside completed additions, Fortis set out a longer runway for capacity creation. The company said it is eyeing the addition of another 1,800 beds between FY27 and FY30, excluding any future inorganic growth opportunities. The statement positions capacity as a central lever for growth, alongside improving occupancy and expanding medical programs. However, Fortis did not provide quarter-wise milestones in the provided disclosures.

Market impact: what the numbers indicate

The quarter’s revenue growth to ₹2,365 crore and PAT rise to ₹271 crore add to the narrative of improving profitability and scale in hospital operations. Margin improvement, with operating EBITDA margin at 22.5% in Q4 FY26 (22.8% for FY26), provides a measurable indicator of operating leverage compared with Q4 FY25 (21.7%) and FY25 (20.4%). Operational metrics were mixed on occupancy, which was slightly lower at 68% versus 69%, but occupied beds increased sharply to 3,339, indicating higher absolute throughput. For investors tracking hospital businesses, ARPOB at ₹2.56 crore and the specialty growth figures provide context on pricing and case mix. Exceptional losses remain an important swing factor in reported profitability, given the large absolute numbers disclosed.

Summary table: key disclosed metrics

Analysis: why this update matters

Fortis’s FY26 performance shows a combination of growth and margin improvement, with revenues at ₹9,128 crore and PAT at ₹1,064 crore. The hospital segment’s scale, noted at 85% of revenues, means changes in occupancy, ARPOB, and bed additions can materially influence consolidated outcomes. The reduction in exceptional losses in Q4 FY26 is also central to the year-on-year PAT comparison and is a key element for readers interpreting the headline profit jump. Finally, the disclosure of bed additions already completed and the plan to add 1,800 beds between FY27 and FY30 offers a concrete capacity roadmap that connects strategy to operational expansion.

Conclusion

Fortis Healthcare closed FY26 with double-digit revenue growth, higher margins, and a stronger Q4 PAT, while also reporting a sharp year-on-year decline in exceptional losses for the March quarter. Management reiterated its focus on brownfield expansion and inorganic opportunities, after adding around 500 beds through acquisitions and a long-term lease. The next set of updates for investors is likely to revolve around progress on the FY27 to FY30 bed addition plan and further steps on inorganic expansion within its focus clusters.